The effects of Momordica charantia on obesity and lipid profiles of mice fed a high-fat diet
2
조회
0
다운로드
5
인용
0
참고문헌
키워드
초록
BACKGROUND/OBJECTIVES: The present study was conducted to investigate the effects of dried Momordica charantia aqueous extracts (MCA) and ethanol extracts (MCE) on obesity and lipid profiles in mice fed a high-fat diet. MATERIALS/METHODS: Forty two ICR mice were randomly divided into six groups. The normal group was fed a basal diet, and other groups were fed a 45% high-fat diet (HFD) for 7 weeks. The normal and HFD groups were also orally administered distilled water each day for 7 weeks. The remaining groups received Momordica charantia extract (0.5 or 1.0 g/kg/day MCA, and 0.5 or 1.0 g/kg/day MCE). In order to measure the anti-obesity and lipid profile improvement effects, body and visceral tissue weight, lipid profiles, plasma insulin levels, hepatic malondialdehyde (MDA) levels and superoxide dismutase (SOD) activity were measured. RESULTS: Both MCA and MCE significantly decreased body and visceral tissue weight relative to those of the HFD group (P < 0.05). Additionally high doses of MCE and MCA significantly reduced the plasmatic insulin levels compared to the HFD groups (P < 0.05) to concentrations comparable to those found in the normal group. MCA and MCE supplementation also significantly modulated the lipid profiles in plasma, liver, and feces compared to mice fed the HFD (P < 0.05). Furthermore MCA and MCE significantly increased hepatic SOD activity, and reduced MDA generation in the liver of the HFD mice (P < 0.05). CONCLUSIONS: Results from the present study suggest that Momordica charantia extracts have anti-obesity effects and the ability to modulate lipid prolife of mice fed a HFD by suppressing body weight gain, visceral tissue weight, plasma and hepatic lipid concentrations, and lipid peroxidation along with increasing lipid metabolism.
Abstract
BACKGROUND/OBJECTIVES: The present study was conducted to investigate the effects of dried Momordica charantia aqueous extracts (MCA) and ethanol extracts (MCE) on obesity and lipid profiles in mice fed a high-fat diet. MATERIALS/METHODS: Forty two ICR mice were randomly divided into six groups. The normal group was fed a basal diet, and other groups were fed a 45% high-fat diet (HFD) for 7 weeks. The normal and HFD groups were also orally administered distilled water each day for 7 weeks. The remaining groups received Momordica charantia extract (0.5 or 1.0 g/kg/day MCA, and 0.5 or 1.0 g/kg/day MCE). In order to measure the anti-obesity and lipid profile improvement effects, body and visceral tissue weight, lipid profiles, plasma insulin levels, hepatic malondialdehyde (MDA) levels and superoxide dismutase (SOD) activity were measured. RESULTS: Both MCA and MCE significantly decreased body and visceral tissue weight relative to those of the HFD group (P < 0.05). Additionally high doses of MCE and MCA significantly reduced the plasmatic insulin levels compared to the HFD groups (P < 0.05) to concentrations comparable to those found in the normal group. MCA and MCE supplementation also significantly modulated the lipid profiles in plasma, liver, and feces compared to mice fed the HFD (P < 0.05). Furthermore MCA and MCE significantly increased hepatic SOD activity, and reduced MDA generation in the liver of the HFD mice (P < 0.05). CONCLUSIONS: Results from the present study suggest that Momordica charantia extracts have anti-obesity effects and the ability to modulate lipid prolife of mice fed a HFD by suppressing body weight gain, visceral tissue weight, plasma and hepatic lipid concentrations, and lipid peroxidation along with increasing lipid metabolism.
참고문헌 (27)
- Haththotuwa RN, "Obesity: A Ticking Time Bomb for Reproductive Health", pp.4~10 (2013), Elsevier
- Yoon KH, "Epidemic obesity and type 2 diabetes in Asia", Lancet, 368, pp.1681~1688 (2006)
- 오상우, "Obesity and Metabolic Syndrome in Korea", Diabetes and Metabolism Journal, 35(6), pp.561~566 (2011), 대한당뇨병학회
- Wu YF, "The current prevalence status of body overweight and obesity in China: data from the China National Nutrition and Health Survey", Zhonghua Yu Fang Yi Xue Za Zhi, 39, pp.316~320 (2005)
- Grundy SM, "Obesity, metabolic syndrome, and cardiovascular disease", J Clin Endocrinol Metab, 89, pp.2595~2600 (2004)
- Parikh NH, "Indigenous plant medicines for health care: treatment of Diabetes mellitus and hyperlipidemia", Chin J Nat Med, 12, pp.335~344 (2014)
- Liao CC, "Elevated blood pressure, obesity, and hyperlipidemia", J Pediatr, 155, pp.79~83 (2009)
- Halliwell B, "Lipid peroxidation: its mechanism, measurement, and significance", Am J Clin Nutr, 57, pp.715S~724S (1993)
- Abd El Sattar El Batran S, "Some toxicological studies of Momordica charantia L. on albino rats in normal and alloxan diabetic rats", J Ethnopharmacol, 108, pp.236~242 (2006)
- Ahmed I, "Hypotriglyceridemic and hypocholesterolemic effects of anti-diabetic Momordica charantia (karela) fruit extract in streptozotocin-induced diabetic rats", Diabetes Res Clin Pract, 51, pp.155~161 (2001)
- Grover JK, "Pharmacological actions and potential uses of Momordica charantia: a review", J Ethnopharmacol, 93, pp.123~132 (2004)
- Chen Q, "Bitter melon (Momordica charantia) reduces adiposity, lowers serum insulin and normalizes glucose tolerance in rats fed a high fat diet", J Nutr, 133, pp.1088~1093 (2003)
- Park SH, "Euonymus alatus prevents the hyperglycemia and hyperlipidemia induced by high-fat diet in ICR mice", J Ethnopharmacol, 102, pp.326~335 (2005)
- Xu SP, "Ameliorating effects of casein glycomacropeptide on obesity induced by high-fat diet in male Sprague-Dawley rats", Food Chem Toxicol, 56, pp.1~7 (2013)
- M'Kada H, "What are the best reference values for a normal serum alanine transaminase activity (ALT)? Impact on the presumed prevalence of drug induced liver injury (DILI)", Regul Toxicol Pharmacol, 60, pp.290~295 (2011)
- Yagi K, "Simple assay for the level of total lipid peroxides in serum or plasma", Methods Mol Biol, 108, pp.101~106 (1998)
- Armstrong D, "Free Radicals in Diagnostic Medicine: A Systems Approach to Laboratory Technology, Clinical Correlations, and Antioxidant Therapy", pp.43~58 (1994), Plenum Press
- Malmstrom BG, "The Enzymes", pp.533~ (1975), Academic Press
- Shih CC, "Effects of Momordica charantia on insulin resistance and visceral obesity in mice on high-fat diet", Diabetes Res Clin Pract, 81, pp.134~143 (2008)
- Popovich DG, "Bitter melon (Momordica charantia)triterpenoid extract reduces preadipocyte viability, lipid accumulation and adiponectin expression in 3T3-L1 cells", Food Chem Toxicol, 48, pp.1619~1626 (2010)
- Srivastava Y, "Effect of Momordica charantia Linn. pomous aqueous extract on cataractogenesis in murrin alloxan diabetics", Pharmacol Res Commun, 20, pp.201~209 (1988)
- Akhtar MS, "Effect of Momordica charantia on blood glucose level of normal and alloxan-diabetic rabbits", Planta Med, 42, pp.205~212 (1981)
- Srivastava Y, "Antidiabetic and adaptogenic properties of Momordica charantia extract: an experimental and clinical evaluation", Phytother Res, 7, pp.285~289 (1993)
- Ahmed I, "Effects of Momordica charantia fruit juice on islet morphology in the pancreas of the streptozotocin-diabetic rat", Diabetes Res Clin Pract, 40, pp.145~151 (1998)
- Leatherdale BA, "Improvement in glucose tolerance due to Momordica charantia (karela)", Br Med J (Clin Res Ed), 282, pp.1823~1824 (1981)
- Jayasooriya AP, "Effects of Momordica charantia powder on serum glucose levels and various lipid parameters in rats fed with cholesterol-free and cholesterol-enriched diets", J Ethnopharmacol, 72, pp.331~336 (2000)
- Wu SJ, "Antioxidant and free radical scavenging activities of wild bitter melon (Momordica charantia Linn. var. abbreviata Ser.)in Taiwan", Lebenson Wiss Technol, 41, pp.323~330 (2008)